Annual EBIT
-$18.49 M
-$957.20 K-5.46%
December 1, 2023
Summary
- As of February 27, 2025, RNAZ annual earnings before interest & taxes is -$18.49 million, with the most recent change of -$957.20 thousand (-5.46%) on December 1, 2023.
- During the last 3 years, RNAZ annual EBIT has fallen by -$16.54 million (-848.56%).
- RNAZ annual EBIT is now -4007.11% below its all-time high of -$450.20 thousand, reached on December 31, 2019.
Performance
RNAZ EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$2.31 M
+$2.88 M+55.45%
September 1, 2024
Summary
- As of February 27, 2025, RNAZ quarterly earnings before interest & taxes is -$2.31 million, with the most recent change of +$2.88 million (+55.45%) on September 1, 2024.
- Over the past year, RNAZ quarterly EBIT has stayed the same.
- RNAZ quarterly EBIT is now -182.14% below its all-time high of $2.81 million, reached on June 30, 2021.
Performance
RNAZ Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$14.88 M
+$2.97 M+16.64%
September 1, 2024
Summary
- As of February 27, 2025, RNAZ TTM earnings before interest & taxes is -$14.88 million, with the most recent change of +$2.97 million (+16.64%) on September 1, 2024.
- Over the past year, RNAZ TTM EBIT has stayed the same.
- RNAZ TTM EBIT is now -90107.27% below its all-time high of -$16.50 thousand, reached on March 1, 2020.
Performance
RNAZ TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RNAZ EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.5% | 0.0% | 0.0% |
| 3 y3 years | -848.6% | 0.0% | 0.0% |
| 5 y5 years | -4007.1% | 0.0% | 0.0% |
RNAZ EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -174.0% | at low | at high | +56.3% | -157.2% | +23.7% |
| 5 y | 5-year | -4007.1% | at low | -182.1% | +56.3% | <-9999.0% | +23.7% |
| alltime | all time | -4007.1% | at low | -182.1% | +56.3% | <-9999.0% | +23.7% |
TransCode Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.31 M(-55.4%) | -$14.88 M(-16.6%) |
| Jun 2024 | - | -$5.19 M(+56.4%) | -$17.86 M(+5.0%) |
| Mar 2024 | - | -$3.32 M(-18.5%) | -$17.00 M(-8.0%) |
| Dec 2023 | -$18.49 M(+5.5%) | -$4.07 M(-23.0%) | -$18.49 M(-5.2%) |
| Sep 2023 | - | -$5.28 M(+21.9%) | -$19.51 M(+5.3%) |
| Jun 2023 | - | -$4.33 M(-9.8%) | -$18.53 M(-1.8%) |
| Mar 2023 | - | -$4.80 M(-5.7%) | -$18.87 M(+7.6%) |
| Dec 2022 | -$17.53 M | -$5.09 M(+18.4%) | -$17.53 M(+15.0%) |
| Sep 2022 | - | -$4.30 M(-8.0%) | -$15.24 M(+14.8%) |
| Jun 2022 | - | -$4.67 M(+34.6%) | -$13.27 M(+129.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$3.47 M(+24.0%) | -$5.79 M(-14.3%) |
| Dec 2021 | -$6.75 M(+246.2%) | -$2.80 M(+20.2%) | -$6.75 M(+43.7%) |
| Sep 2021 | - | -$2.33 M(-182.8%) | -$4.70 M(+35.7%) |
| Jun 2021 | - | $2.81 M(-163.5%) | -$3.46 M(-45.6%) |
| Mar 2021 | - | -$4.43 M(+492.8%) | -$6.37 M(+226.5%) |
| Dec 2020 | -$1.95 M(+333.0%) | - | - |
| Dec 2020 | - | -$747.70 K(-31.6%) | -$1.95 M(+62.2%) |
| Sep 2020 | - | -$1.09 M(+1095.2%) | -$1.20 M(+1012.6%) |
| Jun 2020 | - | -$91.50 K(+454.5%) | -$108.00 K(+554.5%) |
| Mar 2020 | - | -$16.50 K | -$16.50 K |
| Dec 2019 | -$450.20 K | - | - |
FAQ
- What is TransCode Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for TransCode Therapeutics?
- What is TransCode Therapeutics annual EBIT year-on-year change?
- What is TransCode Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly EBIT year-on-year change?
- What is TransCode Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for TransCode Therapeutics?
- What is TransCode Therapeutics TTM EBIT year-on-year change?
What is TransCode Therapeutics annual earnings before interest & taxes?
The current annual EBIT of RNAZ is -$18.49 M
What is the all time high annual EBIT for TransCode Therapeutics?
TransCode Therapeutics all-time high annual earnings before interest & taxes is -$450.20 K
What is TransCode Therapeutics annual EBIT year-on-year change?
Over the past year, RNAZ annual earnings before interest & taxes has changed by -$957.20 K (-5.46%)
What is TransCode Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of RNAZ is -$2.31 M
What is the all time high quarterly EBIT for TransCode Therapeutics?
TransCode Therapeutics all-time high quarterly earnings before interest & taxes is $2.81 M
What is TransCode Therapeutics quarterly EBIT year-on-year change?
Over the past year, RNAZ quarterly earnings before interest & taxes has changed by $0.00 (0.00%)
What is TransCode Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of RNAZ is -$14.88 M
What is the all time high TTM EBIT for TransCode Therapeutics?
TransCode Therapeutics all-time high TTM earnings before interest & taxes is -$16.50 K
What is TransCode Therapeutics TTM EBIT year-on-year change?
Over the past year, RNAZ TTM earnings before interest & taxes has changed by $0.00 (0.00%)